Recro Pharma (REPH) Restructures Acute Care Segment, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance
April 3, 2019 4:05 PM EDTImplements Plan to Reduce Acute Care Segment Staff
CDMO Segment Continues Strong Performance; Company Increases Revenue, Operating Income and EBITDA, as Adjusted* Guidance for 2019
Expects to Become Cash Flow Breakeven During Q3; Cash Flow Positive Second Half of 2019
Plans to Seek Strategic Partner for Commercialization of IV Meloxicam
MALVERN, Pa., April 03, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq: REPH), a revenue generating specialty pharmaceutical company with a high-performing contract development and manufacturing (CDMO)... More
